Form 4: Akari Therapeutics Director Gaslightwala Acquires and Disposes of Ordinary Shares
SEC Form 4
Director Abizer Gaslightwala reports acquiring 40,000,000 and disposing of 70,000,000 ordinary shares of Akari Therapeutics Plc on December 27, 2024.
Summary
- On December 27, 2024, Abizer Gaslightwala, a director of Akari Therapeutics Plc, acquired 40,000,000 ordinary shares at a price of $0.0005 per share.
- The same day, Gaslightwala disposed of 70,000,000 ordinary shares.
- The report was filed on December 30, 2024.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but the large disposal of shares could be interpreted negatively.
Industry Context
Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- Shareholders may react to the director's stock transactions, potentially influencing the stock price.
Key Dates
| Date | Description |
|---|---|
| 12/27/2024 | Date of transaction: Acquisition and disposition of ordinary shares. |
| 12/30/2024 | Date of report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.